Concure Oncology, a Mercer Island, Wash.-based provider of radiation treatment options for women facing early-stage breast cancer, secured $2.5m in funding.
Backers were not disclosed.
The company intends to use the funds to double its field sales organization and focus on training new clinicians across the country.
Led by a nationally-recognized team of leaders from the medical industry, Concure Oncology provides a radiation treatment option for women facing early-stage breast cancer. The company is working with medical centers across the U.S. to bring Breast Microseed Treatment® to patients everywhere. This technique, also known as low-dose-rate brachytherapy, is based on a similar method that has already been proven to treat prostate cancer. The procedure involves the placement of tiny, low dose-rate brachytherapy sources – or Microseeds – into the breast tissue, which release a safe but effective dose of radiation for 2-3 months to the immediate area surrounding the lumpectomy site. Once fully released, the seeds become inert, with no radioactivity remaining.